Format
Sort by
Items per page

Send to

Choose Destination

Best matches for malignant neoplasm of prostate AND patient referral:

Search results

Items: 1 to 20 of 428

1.

Variation in Radiotherapy Referral and Treatment for High-risk Pathological Features after Radical Prostatectomy: Results from a Population-based Study.

Jin CJ, Hanna TP, Cook EF, Miao Q, Brundage MD.

Clin Oncol (R Coll Radiol). 2017 Nov 2. pii: S0936-6555(17)30443-0. doi: 10.1016/j.clon.2017.10.009. [Epub ahead of print]

PMID:
29103854
2.

Development and Internal Validation of a Clinical Risk Score to Predict Pain Response After Palliative Radiation Therapy in Patients With Bone Metastases.

van der Velden JM, Peters M, Verlaan JJ, Versteeg AL, Zhang L, Tsao M, Danjoux C, Barnes E, van Vulpen M, Chow E, Verkooijen HM.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):859-866. doi: 10.1016/j.ijrobp.2017.07.029. Epub 2017 Jul 31.

PMID:
29063851
3.

Low-dose-rate Brachytherapy for Prostate Cancer in Low-resource Settings.

Echevarria MI, Naghavi AO, Abuodeh YA, Ahmed KA, Chevere C, Fernandez D, Yamoah K.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):378-382. doi: 10.1016/j.ijrobp.2017.04.002. Epub 2017 Apr 11.

PMID:
28871987
4.

Implementation rates of uro-oncology multidisciplinary meeting decisions.

Kinnear N, Smith R, Hennessey DB, Bolton D, Sengupta S.

BJU Int. 2017 Nov;120 Suppl 3:15-20. doi: 10.1111/bju.13892. Epub 2017 Sep 14.

5.

Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines.

Henry MA, Howard DH, Davies BJ, Filson CP.

J Urol. 2017 Nov;198(5):1046-1053. doi: 10.1016/j.juro.2017.05.008. Epub 2017 May 6.

PMID:
28487099
6.

Waiting times for cancer patients in Sweden: A nationwide population-based study.

Robertson S, Adolfsson J, Stattin P, Sjövall A, Winnersjö R, Hanning M, Sandelin K.

Scand J Public Health. 2017 May;45(3):230-237. doi: 10.1177/1403494817693695. Epub 2017 Mar 8.

PMID:
28443490
7.

How Men with Prostate Cancer Choose Specialists: A Qualitative Study.

Jiang T, Stillson CH, Pollack CE, Crossette L, Ross M, Radhakrishnan A, Grande D.

J Am Board Fam Med. 2017 Mar-Apr;30(2):220-229. doi: 10.3122/jabfm.2017.02.160163.

8.

Second opinions from urologists for prostate cancer: Who gets them, why, and their link to treatment.

Radhakrishnan A, Grande D, Mitra N, Bekelman J, Stillson C, Pollack CE.

Cancer. 2017 May 15;123(6):1027-1034. doi: 10.1002/cncr.30412. Epub 2016 Nov 7.

PMID:
28263389
9.

Monte Carlo decision curve analysis using aggregate data.

Hozo I, Tsalatsanis A, Djulbegovic B.

Eur J Clin Invest. 2017 Feb;47(2):176-183. doi: 10.1111/eci.12723.

PMID:
28042671
10.

Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial.

Chambers SK, Occhipinti S, Foley E, Clutton S, Legg M, Berry M, Stockler MR, Frydenberg M, Gardiner RA, Lepore SJ, Davis ID, Smith DP.

J Clin Oncol. 2017 Jan 20;35(3):291-297. doi: 10.1200/JCO.2016.68.8788. Epub 2016 Nov 21.

PMID:
27870567
11.

Yonder: Oral cancer, PSA, dizziness, and vaginal health.

Rashid A.

Br J Gen Pract. 2016 Nov;66(652):574. No abstract available.

12.

Elevated prostate specific antigen and reduced 10-year survival among a cohort of Danish men consecutively referred from primary care to an urological department during 2005-2006.

Hillig T, Nielsen TK, Hansen SI, Nygaard AB, Sölétormos G.

Scand J Clin Lab Invest. 2017 Feb;77(1):27-35. Epub 2016 Oct 20.

PMID:
27762145
13.

The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two-Center Validation Study.

Dell'Oglio P, Karnes RJ, Gandaglia G, Fossati N, Stabile A, Moschini M, Cucchiara V, Zaffuto E, Karakiewicz PI, Suardi N, Montorsi F, Briganti A.

Prostate. 2017 Feb;77(3):263-273. doi: 10.1002/pros.23265. Epub 2016 Oct 18.

PMID:
27753114
14.

Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre.

Gnanapragasam VJ, Thurtle D, Srinivasan A, Volanis D, George A, Lophatananon A, Stearn S, Warren AY, Lamb AD, Shaw G, Sharma N, Thomas BC, Tran MG, Neal DE, Shah NC.

BJU Int. 2016 Nov;118(5):779-784. doi: 10.1111/bju.13513. Epub 2016 May 24.

15.

European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.

Foley RW, Maweni RM, Gorman L, Murphy K, Lundon DJ, Durkan G, Power R, O'Brien F, O'Malley KJ, Galvin DJ, Brendan Murphy T, William Watson R.

BJU Int. 2016 Nov;118(5):706-713. doi: 10.1111/bju.13437. Epub 2016 Feb 29.

16.

Using a Mystery-Caller Approach to Examine Access to Prostate Cancer Care in Philadelphia.

Pollack CE, Ross ME, Armstrong K, Branas CC, Rhodes KV, Bekelman JE, Wentz A, Stillson C, Radhakrishnan A, Oyeniran E, Grande D.

PLoS One. 2016 Oct 10;11(10):e0164411. doi: 10.1371/journal.pone.0164411. eCollection 2016.

17.

Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer.

Ilg AM, Laviana AA, Kamrava M, Veruttipong D, Steinberg M, Park SJ, Burke MA, Niedzwiecki D, Kupelian PA, Saigal C.

Brachytherapy. 2016 Nov - Dec;15(6):760-767. doi: 10.1016/j.brachy.2016.08.008. Epub 2016 Oct 4.

PMID:
27720202
18.

Clarifying the PSA grey zone: The management of patients with a borderline PSA.

Ross T, Ahmed K, Raison N, Challacombe B, Dasgupta P.

Int J Clin Pract. 2016 Nov;70(11):950-959. doi: 10.1111/ijcp.12883. Epub 2016 Sep 27. Review.

PMID:
27672001
19.

Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening.

Hutchinson R, Akhtar A, Haridas J, Bhat D, Roehrborn C, Lotan Y.

Cancer. 2016 Dec 15;122(24):3785-3793. doi: 10.1002/cncr.30330. Epub 2016 Sep 22.

PMID:
27658175

Supplemental Content

Loading ...
Support Center